RNA Supply Chain Videos

31. Primates, Patents, And Progress: Advancements In Rational LNP Design 2/24/2026

    In this opening Advancing RNA Live clip, NanoVation Therapeutics’ Dominik Witzigmann and Stealth Co’s John Zuris share the scientific advancements they’ve been watching most keenly in the LNP space, as well as some of the evolutions they’re seeing in the overall quality of our RNA-LNP products.

32. Don't Ignore These Functional Areas In Your RNA Therapeutic's Regulatory Story 5/10/2024

    Explore two functional areas that Advancing RNA panelists consider most essential to telling an RNA product’s “story” thoroughly to regulators.

33. Enabling GMP Production Of sgRNA For CRISPR-Based Cell And Gene Therapies 10/28/2024

    Explore critical steps and key regulatory requirements for developing CRISPR therapeutics and gain practical advice on how to avoid common pitfalls.

34. End-To-End Cold Chain Management: A Next-Generation Approach 2/26/2024

    Three experts in cold chain management walk through the advantages of end-to-end platforms for bulk drug substance management.

35. The State of the Linear mRNA Supply Chain—In Brief

    In this clip, Sanofi’s Greg Troiano kickstarts our discussion on some of the advances he’s seen in the supply chain for linear mRNA-LNP products, both in terms of supply availability and supplier capability.

36. The Strategic Shift(s) In gRNA CMC 4/29/2026

    In this opening Advancing RNA Live clip, panelists Max De Long, April Sena, and Venkat Krishnamurthy share the biggest scientific and manufacturing breakthrough made in the world of gRNA production over the past year. 

37. Next Generation GMP Facility For CRISPR Based Therapies 3/14/2023

    Explore a state-of-the-art GMP facility focused on CRISPR based Cell and Gene therapies with helping temperature controlled warehouse and multiple synthesis suites.

38. The 3 C's Of mRNA-LNP Material Sourcing

    In response to an audience poll question gauging which cGMP materials have proven the most difficult to source, our speakers provide additional clarity around which IVT & LNP-related materials today are more “commoditized”.

39. Why We Still Haven't Solved mRNA Scale-Up 10/15/2025

    While we can make lots of mRNA at a smaller scale, when it comes to scaling up to kg quantities of mRNA, our current batch processes leave a lot to be desired. Together, Stu Sundseth of Tune Therapeutics and Christian Dohmen of Ethris unpack the biggest barriers to scaling IVT to achieve the desired yield and quality of mRNA, offering their take on how the field is innovating to overcome these issues. 

40. The Evolving CMC Landscape For mRNA-LNPs 2/24/2026

    In this Advancing RNA Live clip, CMC consultant Sujit Jain unpacks the levels of maturity he’s observed in process and analytical development, as well as supply chain. While vaccines and liver-targeting therapeutics boast what we can call a reproducible platform today, targeted LNP therapies introduce a handful of scale-up sensitivities and characterization hurdles.